Literature DB >> 12872254

A genetic and phenotypic analysis in Spanish spinal muscular atrophy patients with c.399_402del AGAG, the most frequently found subtle mutation in the SMN1 gene.

Ivon Cuscó1, Eva López, Carolina Soler-Botija, María Jesús Barceló, Montserrat Baiget, Eduardo F Tizzano.   

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations in the SMN1 (survival motor neuron) gene. It is classified by age of onset and maximal motor milestones achieved in type I, II, and III (severe, intermediate, and mild form, respectively). Of 369 unrelated SMA patients who were investigated for homozygous deletions in the SMN1 gene, 18 patients (4.8%) revealed at least one copy of exon 7. A 4-bp deletion in exon 3 (c.399_402delAGAG) was detected in 15 patients from 10 families. This mutation was associated with a large spectrum of phenotypes from type I to asymptomatic patients. Five patients from two consanguineous families were homozygous for the mutation with diverse mild phenotypes. Determination of the SMN2 copy number showed that the presence of two or three copies generally correlated with a better evolution. RT-PCR studies of SMN transcripts in control and patients with the same SMN2 copy number showed that the full-length/Delta7 ratio is influenced by the SMN1 genotype although it seems independent of the SMN2 copy number. Moreover, protein analysis in these patients showed a reduction in SMN protein in compound heterozygous patients (c.399_402delAGAG/deletion) when compared with homozygous c.399_402delAGAG/c.399_402delAGAG patients. Microsatellite DNA markers flanking the SMA locus revealed the occurrence of the 4-bp deletion in the background of the same haplotype, suggesting that a single mutational event was involved in the 10 families. The geographic origins of ancestors point to a founder effect from the south and east of Spain. The c.399_402delAGAG, which is to date unique to the Spanish population, constitutes the most frequently found subtle mutation in SMA. Hum Mutat 22:136-143, 2003. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12872254     DOI: 10.1002/humu.10245

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  16 in total

1.  Clinical utility gene card for: proximal spinal muscular atrophy.

Authors:  Sabine Rudnik-Schöneborn; Thomas Eggermann; Wolfram Kress; Henny H Lemmink; Jan-Maarten Cobben; Klaus Zerres
Journal:  Eur J Hum Genet       Date:  2012-04-18       Impact factor: 4.246

2.  Clinical utility gene card for: Proximal spinal muscular atrophy (SMA) - update 2015.

Authors:  Sabine Rudnik-Schöneborn; Thomas Eggermann; Wolfram Kress; Henny H Lemmink; Jan-Maarten Cobben; Klaus Zerres
Journal:  Eur J Hum Genet       Date:  2015-05-20       Impact factor: 4.246

Review 3.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

4.  Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability.

Authors:  Eva Also-Rallo; Laura Alías; Rebeca Martínez-Hernández; Lidia Caselles; María J Barceló; Montserrat Baiget; Sara Bernal; Eduardo F Tizzano
Journal:  Eur J Hum Genet       Date:  2011-05-25       Impact factor: 4.246

5.  A founder mutation in the CLCNKB gene causes Bartter syndrome type III in Spain.

Authors:  Juan Rodríguez-Soriano; Alfredo Vallo; Gustavo Pérez de Nanclares; José Ramón Bilbao; Luis Castaño
Journal:  Pediatr Nephrol       Date:  2005-05-05       Impact factor: 3.714

6.  Genetic findings of Cypriot spinal muscular atrophy patients.

Authors:  L Theodorou; P Nicolaou; P Koutsou; A Georghiou; V Anastasiadou; G Tanteles; T Kyriakides; E Zamba-Papanicolaou; K Christodoulou
Journal:  Neurol Sci       Date:  2015-05-28       Impact factor: 3.307

7.  Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene.

Authors:  Laura Alías; Sara Bernal; Pablo Fuentes-Prior; María Jesus Barceló; Eva Also; Rebeca Martínez-Hernández; Francisco J Rodríguez-Alvarez; Yolanda Martín; Elena Aller; Elena Grau; Ana Peciña; Guillermo Antiñolo; Enrique Galán; Alberto L Rosa; Miguel Fernández-Burriel; Salud Borrego; José M Millán; Concepción Hernández-Chico; Montserrat Baiget; Eduardo F Tizzano
Journal:  Hum Genet       Date:  2008-12-03       Impact factor: 4.132

8.  A novel mutation at the N-terminal of SMN Tudor domain inhibits its interaction with target proteins.

Authors:  Tomohiro Kotani; Retno Sutomo; Teguh Haryo Sasongko; Ahmad Hamim Sadewa; Toshinori Minato; Emiko Fujii; Shoichi Endo; Myeong Jin Lee; Hitoshi Ayaki; Yosuke Harada; Masafumi Matsuo; Hisahide Nishio
Journal:  J Neurol       Date:  2007-04-06       Impact factor: 4.849

9.  Subtle mutations in the SMN1 gene in Chinese patients with SMA: p.Arg288Met mutation causing SMN1 transcript exclusion of exon7.

Authors:  Qu Yu-Jin; Du Juan; Li Er-zhen; Bai Jin-li; Jin Yu-wei; Wang Hong; Song Fang
Journal:  BMC Med Genet       Date:  2012-09-20       Impact factor: 2.103

10.  SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings.

Authors:  I Cuscó; M J Barceló; R Rojas-García; I Illa; J Gámez; C Cervera; A Pou; G Izquierdo; M Baiget; E F Tizzano
Journal:  J Neurol       Date:  2005-06-28       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.